Adoram Therapeutics Revenue

Biotechnology Research • Carouge, Geneva, Switzerland • 1-10 Employees

Adoram Therapeutics revenue & valuation

Annual revenue	$342,220
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,100,000
Total funding	$1,415,500

Key Contact at Adoram Therapeutics

David Pejoski

Cofounder, Co-CEO, COO, Board Member

Company overview

Headquarters	Carouge, Geneva, Switzerland
Phone number	+4123332367
Website	adoram.ch
NAICS	541714
Founded	2022
Employees	1-10
Socials

About Adoram Therapeutics

Adoram Therapeutics is an Swiss-based biotech startup focused on developing cutting-edge therapeutic assets. Our pipeline includes two differentiated preclinical-stage allosteric modulators, backed by compelling preclinical proof-of-concept (PoC) data from ex vivo human and in vivo mouse studies. Asset 1 is a negative allosteric modulator of A2AR, a best-in-class immuno-enhancer with excellent potential for immunotherapy in solid tumors. This asset is poised to synergize with existing and emerging blockbuster therapies, including immune checkpoint blockade (ICB) monoclonal antibodies, to offer enhanced efficacy in cancer treatments. Asset 2 is a first-in-class positive allosteric modulator of A2AR, with the potential to transform the treatment of various inflammatory, immunological, and metabolic diseases. This asset has wide-ranging therapeutic applications aimed at improving patient outcomes across multiple disease areas. Our allosteric approach to drug development offers a safer, more targeted, and effective alternative to conventional 'orthosteric' small molecules. At Adoram Therapeutics, we are committed to developing the next generation of small molecule medicines that improve the lives of patients worldwide.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

Adoram Therapeutics has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

Explore Adoram Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2024-11-24	12	$115,500
2025-03-25	2	N/A
2025-06-05	9	$1,300,000

Funding Insights

$1,415,500

Total funding amount

$1,300,000

Most recent funding amount

Number of funding rounds

Adoram Therapeutics Tech Stack

Discover the technologies and tools that power Adoram Therapeutics's digital infrastructure, from frameworks to analytics platforms.

reCAPTCHA

Security

Underscore.js

JavaScript libraries

Slick

JavaScript libraries

Elementor Header & Footer Builder

WordPress plugins

WPForms

Form builders

Elementor

Page builders

jQuery Migrate

JavaScript libraries

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

PHP

Programming languages

HSTS

Security

WordPress

Blogs

Frequently asked questions

Adoram Therapeutics is located in Carouge, Geneva, CH.

You can reach Adoram Therapeutics at +4123332367.

Adoram Therapeutics generates an estimated annual revenue of $342,220. This revenue figure reflects the company's market position and business performance in its industry.

Adoram Therapeutics has an estimated valuation of $1,100,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Adoram Therapeutics was founded in 2022, making it 4 years old. The company has established itself as a significant player in its industry over this time.

Adoram Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Adoram Therapeutics has raised a total of $1,415,500 across 3 funding rounds. This investment has helped the company grow and expand its operations.

Key Contact at Adoram Therapeutics

David Pejoski

Cofounder, Co-CEO, COO, Board Member

4.8

40,000 users